Marker Therapeutics Company
Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
Technology:
CAR-T therapy
Industry:
Public
Headquarters:
Minneapolis, Minnesota, United States
Founded Date:
1992-01-01
Employees Number:
51-100
Funding Status:
IPO
Investors Number:
3
Total Funding:
96600000
Last Funding Date:
2022-12-13
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership